Welcome to our dedicated page for West Pharm Svcs news (Ticker: WST), a resource for investors and traders seeking the latest updates and insights on West Pharm Svcs stock.
West Pharmaceutical Services, Inc. (NYSE: WST) is a provider of injectable solutions and services that support the containment and delivery of medicines for pharmaceutical, biotechnology and generic drug companies. News related to WST often centers on its role in injectable drug administration, its proprietary product platforms and its contract manufacturing activities.
Company announcements frequently include quarterly and annual financial results, updates to revenue and earnings guidance, and details on performance in its Proprietary Products and Contract-Manufactured Products segments. Releases have highlighted trends in High-Value Product Components and High-Value Product Delivery Devices, as well as demand for self-injection devices for therapeutic areas such as obesity and diabetes.
West’s news flow also covers product and technology developments. Recent examples include the launch of the West Synchrony™ Prefillable Syringe System, described as a system-level solution for biologics and vaccines, and updates on the SmartDose® on-body delivery platform. The company has announced a definitive agreement to sell manufacturing and supply rights for the SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie, along with related information on continued supply and ongoing project commitments.
Investors following WST news will also see disclosures about capital allocation, such as dividends and share repurchases, as well as governance and leadership changes reported via press releases and Form 8-K filings. Conference participation and investor presentations are regularly announced, providing additional context on the company’s strategy and financial outlook. This news page aggregates such updates so readers can review West’s latest reported developments, financial communications and product-related announcements in one place.
West Pharmaceutical Services reported its fourth-quarter and full-year 2021 financial results, showcasing significant growth. Q4 net sales reached $730.8 million, a 26% increase, with organic growth at 28.3%. Full-year sales totaled $2.832 billion, up 31.9%. Reported diluted EPS for Q4 was $1.93, a 49.6% rise, and $8.67 for the year, up 89.7%. The company projects 2022 net sales between $3.050 billion and $3.075 billion, with diluted EPS expected between $9.20 and $9.35. They noted strong demand in their Proprietary Products segment and plans for future growth.
West Pharmaceutical Services, a leader in injectable drug administration, will announce its fourth-quarter and full-year 2021 financial results on February 17, 2022, before the market opens. A conference call to discuss these results is scheduled for 9:00 a.m. ET on the same day. Participants can join by calling 877-930-8295 (U.S.) or 253-336-8738 (International), using conference ID 1986145. An archive of the call will be available for review until February 24, 2022. For more information, visit www.westpharma.com.
West Pharmaceutical Services (WST) has entered an exclusive supply and technology agreement with Corning (GLW) to enhance injectable drug delivery systems. This multimillion-dollar partnership seeks to expand Corning’s Valor® Glass technology, promoting advanced packaging solutions for the pharmaceutical industry aimed at improving patient safety and access to treatments. The collaboration combines West’s NovaPure® components with Corning’s Valor Glass, optimizing manufacturing processes and regulatory navigation for biopharma producers.
West Pharmaceutical Services (WST) announced a $0.18 per share dividend for Q1 2022, payable on February 2, 2022, to shareholders on record by January 19, 2022. Additionally, the company's Board of Directors approved a share repurchase program for 2022, allowing the buyback of up to 650,000 shares. This program aims to enhance shareholder value and is expected to conclude by December 31, 2022, following the expiration of a previous buyback.
West Pharmaceutical Services (NYSE: WST) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 11:15 a.m. EST. The event will be held virtually, allowing investors to access a live audio webcast in the "Investors" section of the company's website. West is a leader in injectable drug solutions, generating over $2.15 billion in sales during fiscal year 2020. With nearly 10,000 employees across 50 sites, West provides over 40 billion components and devices annually.
West Pharmaceutical Services (NYSE: WST) will participate in the Jefferies London Healthcare Conference from November 16-18, 2021, with a Fireside Chat on November 16, 2021, at 5:40 p.m. GMT. The company will also attend the Stephens Investment Conference in Nashville, TN, from December 1-3, 2021, featuring a Fireside Chat on December 3, 2021, at 11:00 a.m. CST. Webcasts for both events will be available on the company's website, with replays accessible for 90 days. West, a leader in injectable solutions, generated over $2.15 billion in sales in FY 2020.
West Pharmaceutical Services reported a strong Q3 2021, with net sales of $706.5 million, a 28.9% increase year-over-year. Reported diluted EPS rose 112% to $2.31. The company raised its full-year net sales guidance to $2.800-$2.810 billion and adjusted diluted EPS guidance to $8.40-$8.50. A quarterly dividend of $0.18 per share was approved, reflecting a 5.9% increase. Sales growth was driven by proprietary products, particularly from the High-Value Product portfolio.
Summary not available.
West Pharmaceutical Services announced the launch of its DeltaCube™ Modeling Platform and NovaGuard® SA Pro Safety System for 0.5mL Standard Glass Syringes at Interphex from October 19-21 in New York. The DeltaCube™ platform aids in vial integrity modeling, enhancing decision-making in container closure systems. The NovaGuard® SA Pro system expands product offerings for pre-filled syringes, addressing safety with innovative features to protect against needlestick injuries. This initiative reflects a strategic response to market demands for safer and more efficient drug delivery solutions.
West Pharmaceutical Services (NYSE: WST) will announce third-quarter 2021 financial results on October 28, 2021, before market opening. A conference call will take place at 9:00 a.m. Eastern Time to discuss the results and future business outlook. Interested participants can join by calling 877-930-8295 (U.S.) or 253-336-8738 (International) with conference ID 5587559. The event will be streamed live on the company's website, with an archived version available afterward until November 4, 2021.